Floatz logo

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR, CSF-1R, CSF-1-R, MACROPHAGE COLONYSTIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)), HUMANIZED MONOCLONAL ANTIBODY

Ovarian Adenocarcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Ovarian Adenocarcinoma cohort.

Asset / SponsorPhaseRating
IERAMILIMAB
Novartis Pharmaceuticals
Phase 2B
Cyclophosphamide
TCR2 Therapeutics
Phase 1/2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Niraparib
CanariaBio Inc.
Phase 2CCC

View all 15 →

Same molecule, other indications

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CSF1R (COLONY STIMULATING FACTOR 1 RECEPTOR, CSF-1R, CSF-1-R, MACROPHAGE COLONYSTIMULATING FACTOR 1 RECEPTOR, C-FMS, FMS, CD115)), HUMANIZED MONOCLONAL ANTIBODY is also rated in:

fallopian tube clear cell adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
fallopian tube adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
fallopian tube endometrioid adenocarcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →